| scholarly article | Q13442814 |
| P50 | author | Prahlad T. Ram | Q38320859 |
| P2093 | author name string | Paul D Smith | |
| Michael A Davies | |||
| Kakajan Komurov | |||
| Wanleng Deng | |||
| Scott E Woodman | |||
| Y N Vashisht Gopal | |||
| P2860 | cites work | High-throughput oncogene mutation profiling in human cancer | Q57693480 |
| Expression of insulin-like growth factor-1 receptor (IGF-1R) and p27Kip1 in melanocytic tumors: a potential regulatory role of IGF-1 pathway in distribution of p27Kip1 between different cyclins | Q73517478 | ||
| Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways | Q74591017 | ||
| Mutations of PIK3CA are rare in cutaneous melanoma | Q82986814 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers | Q27851426 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants | Q28287782 | ||
| Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set | Q28389579 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) | Q33717222 | ||
| Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation | Q34109986 | ||
| Use of human tissue to assess the oncogenic activity of melanoma-associated mutations | Q34716087 | ||
| AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer | Q34990362 | ||
| Epigenetic PTEN silencing in malignant melanomas without PTEN mutation | Q35745799 | ||
| Management of cutaneous melanoma | Q35877006 | ||
| Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. | Q36609858 | ||
| A novel AKT3 mutation in melanoma tumours and cell lines | Q36944047 | ||
| Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma | Q36982042 | ||
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 | ||
| Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition | Q37331610 | ||
| TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN | Q37347217 | ||
| Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) | Q38300326 | ||
| Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells | Q39799421 | ||
| Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma | Q39971699 | ||
| Pharmacodynamic markers of perifosine efficacy | Q40032914 | ||
| IGF1 promotes resistance to apoptosis in melanoma cells through an increased expression of BCL2, BCL-X(L), and survivin | Q40035487 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor | Q40164535 | ||
| Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 | ||
| Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 | ||
| Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines | Q42818580 | ||
| AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity | Q43211411 | ||
| PI3-kinase subunits are infrequent somatic targets in melanoma. | Q43461378 | ||
| A module of negative feedback regulators defines growth factor signaling | Q45345602 | ||
| The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel | Q46825496 | ||
| Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma | Q53640355 | ||
| P433 | issue | 21 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell death | Q2383867 |
| P304 | page(s) | 8736-8747 | |
| P577 | publication date | 2010-10-19 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | |
| P478 | volume | 70 |
| Q37106124 | 1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma. |
| Q39465525 | 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) facilitates curcumin-induced melanoma cell apoptosis by enhancing ceramide accumulation, JNK activation, and inhibiting PI3K/AKT activation |
| Q92376061 | A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors |
| Q50099671 | A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors |
| Q92794476 | A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma |
| Q91787280 | A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma |
| Q39207634 | A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. |
| Q42791397 | A systems biology approach to personalizing therapeutic combinations |
| Q42514738 | ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma |
| Q53701225 | AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma. |
| Q27851932 | AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines |
| Q37727061 | Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma |
| Q35033377 | Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas |
| Q28069018 | Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma |
| Q37595877 | Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de-differentiated state |
| Q38211773 | Adaptive resistance to RAF inhibitors in melanoma |
| Q38042457 | Affinity proteomics: the role of specific binding reagents in human proteome analysis |
| Q42632659 | Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. |
| Q49961734 | Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. |
| Q28481390 | BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner |
| Q37702515 | BRAF and beyond: Tailoring strategies for the individual melanoma patient |
| Q58712577 | BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1 |
| Q27006853 | Beyond BRAF: where next for melanoma therapy? |
| Q38371675 | Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer |
| Q37687154 | Blockade efficacy of MEK/ERK-dependent autophagy enhances PI3K/Akt inhibitor NVP-BKM120's therapeutic effectiveness in lung cancer cells |
| Q39325158 | Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner |
| Q42206973 | Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion |
| Q35146471 | Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition |
| Q48279436 | Comparison of Xiphophorus and human melanoma transcriptomes reveals conserved pathway interactions |
| Q34220097 | Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines |
| Q35700459 | Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF |
| Q38238604 | Consequences of feedback in signal transduction for targeted therapies. |
| Q38940098 | Converting biology into clinical benefit: lessons learned from BRAF inhibitors |
| Q42175635 | Counteracting oxidative phosphorylation-mediated resistance of melanomas to MAPK pathway inhibition |
| Q38757522 | Crosstalk signaling in targeted melanoma therapy |
| Q37635839 | Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells |
| Q35841043 | EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib |
| Q36507554 | Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma |
| Q27852994 | Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma |
| Q37457602 | Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models |
| Q36239253 | Embryonic signaling in melanoma: potential for diagnosis and therapy |
| Q35670413 | Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells |
| Q90460706 | Epigenetic Mechanisms of Escape from BRAF Oncogene Dependency |
| Q35018167 | Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas |
| Q36021891 | ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. |
| Q36134032 | Evaluation of Protein Profiles From Treated Xenograft Tumor Models Identifies an Antibody Panel for Formalin-fixed and Paraffin-embedded (FFPE) Tissue Analysis by Reverse Phase Protein Arrays (RPPA) |
| Q35675442 | Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. |
| Q37708952 | FOXC1 promotes melanoma by activating MST1R/PI3K/AKT. |
| Q36373537 | Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. |
| Q43147493 | Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. |
| Q37058301 | GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells. |
| Q37955107 | Genetic alterations of PTEN in human melanoma |
| Q90459618 | Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations |
| Q35519172 | Genotype-Dependent Sensitivity of Uveal Melanoma Cell Lines to Inhibition of B-Raf, MEK, and Akt Kinases: Rationale for Personalized Therapy |
| Q34667738 | Genotyping of cutaneous melanoma |
| Q92946120 | HDAC Inhibition Enhances the In Vivo Efficacy of MEK Inhibitor Therapy in Uveal Melanoma |
| Q27334924 | Impact of Combined mTOR and MEK Inhibition in Uveal Melanoma Is Driven by Tumor Genotype |
| Q38160220 | Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function |
| Q38402255 | Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells |
| Q36698266 | Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy |
| Q39212742 | Inhibition of both BRAF and MEK in BRAF(V600E) mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. |
| Q38949618 | Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma |
| Q39396267 | Inhibition of metadherin sensitizes breast cancer cells to AZD6244 |
| Q35746524 | Inhibitors of pan-PI3K Signaling Synergize with BRAF or MEK Inhibitors to Prevent BRAF-Mutant Melanoma Cell Growth |
| Q37308813 | It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma |
| Q36553576 | Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. |
| Q90194041 | MAPK Pathway under Chronic Copper Excess in Green Macroalgae (Chlorophyta): Involvement in the Regulation of Detoxification Mechanisms |
| Q38238597 | MAPK pathway inhibition in melanoma: resistance three ways |
| Q37161421 | MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines |
| Q92531455 | MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells |
| Q54536549 | MEK'ing the Most of p53 Reactivation Therapy in Melanoma |
| Q36682132 | MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. |
| Q39115959 | Matrine Activates PTEN to Induce Growth Inhibition and Apoptosis in V600EBRAF Harboring Melanoma Cells |
| Q39329582 | Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma |
| Q58547833 | Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma |
| Q36793441 | Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3 |
| Q38146707 | Melanoma mutagenesis and aberrant cell signaling |
| Q38891959 | Metastatic melanoma moves on: translational science in the era of personalized medicine. |
| Q34283481 | Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells |
| Q53205249 | Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma |
| Q34438536 | Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target |
| Q37830845 | Mutant BRAF Melanomas—Dependence and Resistance |
| Q37301530 | Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. |
| Q37689575 | NRAS mutant melanoma: biological behavior and future strategies for therapeutic management |
| Q38148747 | Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma |
| Q37660498 | Network quantification of EGFR signaling unveils potential for targeted combination therapy. |
| Q38775165 | Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer |
| Q38095892 | Obesity and melanoma: exploring molecular links |
| Q54464748 | Overcoming resistance to MAPK pathway inhibitors. |
| Q34761941 | PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression |
| Q26865736 | Pathways and therapeutic targets in melanoma |
| Q33399049 | Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma |
| Q27852623 | Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. |
| Q37598084 | Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. |
| Q35320304 | Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma |
| Q38757884 | Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. |
| Q41982963 | Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines. |
| Q37866945 | Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers |
| Q38256348 | Profile of selumetinib and its potential in the treatment of melanoma |
| Q39551441 | Protein Kinase D3 Sensitizes RAF Inhibitor RAF265 in Melanoma Cells by Preventing Reactivation of MAPK Signaling |
| Q42998414 | Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma |
| Q82182829 | Regulation, Role, and Targeting of Akt in Cancer |
| Q39224151 | Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents |
| Q37625751 | Resistance to RAF inhibitors revisited |
| Q26739717 | Resistant mechanisms to BRAF inhibitors in melanoma |
| Q27851698 | Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. |
| Q39428029 | Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition |
| Q38963788 | Role of Runx2 in crosstalk between Mek/Erk and PI3K/Akt signaling in MCF-10A cells |
| Q92715575 | SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC |
| Q37990969 | Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma |
| Q54310457 | Selumetinib for the treatment of cancer |
| Q36560775 | Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status |
| Q39128830 | Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles |
| Q36276136 | Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf |
| Q38764368 | Somatic driver mutations in melanoma. |
| Q36872318 | Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling |
| Q36788057 | Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer |
| Q37401151 | TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF- Mutant Melanoma |
| Q38026624 | Targeted Therapies for Metastatic Melanoma |
| Q41859238 | Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm |
| Q38082327 | Targeted therapy for melanoma: rational combinatorial approaches |
| Q37269197 | Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q39013913 | Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma |
| Q38124821 | Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma |
| Q26865765 | Targeting cancer with kinase inhibitors |
| Q36141097 | Targeting drivers of melanoma with synthetic small molecules and phytochemicals |
| Q35859282 | Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies |
| Q36902066 | Targeting mutant NRAS signaling pathways in melanoma |
| Q64055352 | Targeting the ERK Signaling Pathway in Melanoma |
| Q27687198 | Targeting the RAS oncogene |
| Q37945533 | The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? |
| Q35744471 | The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells |
| Q35911227 | The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. |
| Q34104135 | The MAPK pathway as an apoptosis enhancer in melanoma |
| Q44073293 | The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. |
| Q37997546 | The Role of the PI3K-AKT Pathway in Melanoma |
| Q39353140 | The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor |
| Q37626102 | The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma |
| Q34244242 | The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms |
| Q35140947 | The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma |
| Q35810176 | The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence |
| Q39383689 | Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies |
| Q35775241 | Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. |
| Q38219616 | Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). |
| Q36382520 | Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity |
| Q35640196 | Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma |
| Q33808166 | WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. |
| Q39456830 | mTOR Signaling Confers Resistance to Targeted Cancer Drugs. |
Search more.